A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

• Główni autorzy: Yue Fei (Autor), Na Li (Autor), Weilin Qian (Autor), Yang Fan (Autor), Yu Shen (Autor), Quanren Wang (Autor), Kristi McLendon (Autor), Kai Shen (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

IntroductionThymic stromal lymphopoietin (TSLP) is integral to inducing innate and T helper two cell inflammation that leads to clinical symptoms of asthma. SHR-1905 is a humanized immunoglobulin G1 kappa monoclonal antibody that inhibits TSLP bioactivity, developed for the treatment of severe uncon...